Sanuwave Health, Inc. received a notice from Nasdaq on September 23, 2026, indicating its Market Value of Listed Securities fell below the $50 million minimum requirement for continued listing on The Nasdaq Global Market over the last 30 consecutive business days. The company has an 180-day compliance period ending March 22, 2027, to restore compliance by maintaining a market value of at least $50 million for ten consecutive business days. Failure to meet this threshold may result in delisting, though the company may apply to transfer to The Nasdaq Capital Market if applicable requirements are satisfied. Sanuwave Health operates in the medical technology industry, developing and commercializing neuromodulation therapies.
